Navigation Links
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
Date:2/6/2009

red number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our actual burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in our projections and forward-looking statements.

BCRXW

                            BIOCRYST PHARMACEUTICALS, INC.
                                  FINANCIAL SUMMARY

    Statements of Operations (Unaudited)
      (in thousands,
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... (PRWEB) March 27, 2015 The consumption ... back of the recession and high prices in 2008. ... has recovered and keeps on gaining momentum now. , ... stands at more than 100,000 thousand tonnes. No considerable ... Meantime, the global capacity rocketed during 2012-2013, registering 11% ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... leader in liquid photopurification, announced today that the ... approval for the continued trading of SurePure ("SURP") ... execution venture marketplace for entrepreneurial and development stage ... Markets Group introduced standards and eligibility requirements designed ...
(Date:3/27/2015)... March 27, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the ... today that an Investigational New Drug (IND) application ... rheumatoid arthritis has been accepted for review by ... In September 2012, MedImmune, the global ...
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
Breaking Biology Technology:World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7
... Johnson Controls, Inc. is introducing a new building ... Authorized Building Control Specialist (ABCS) network. , ,The Facility ... is scalable to provide control to a wide variety ... quick access to information from anywhere in the system, ...
... sector, she began to notice a certain pattern: Scientists with ... business world to be a much different place than academia, ... ,"Along the way, I realized that it was that people ... product just as effectively as a competitor," Villars said. "I ...
... suburban Madison will gain early review and easier access ... Alumni Research Foundation (WARF) has available for licensing, under ... Promega announced Tuesday. , ,If Promega finds a ... makes it easier to license the technology and develop ...
Cached Biology Technology:Can tech people be business leaders? Upcoming seminar may have the answer 2Can tech people be business leaders? Upcoming seminar may have the answer 3Promega to get early access to WARF technologies under new agreement 2
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... ROCKVILLE, Md. -- Several members of the American Society ... or foreign associates of the U.S. National Academy of ... in original research. Three current ASPB members were ... Birchler , Curators Professor of Biological Sciences, University of ...
... Callaghan, a researcher at the Royal Swedish Academy of Sciences, ... and permafrost. "The changes we see are dramatic. ... deviate from the norm when compared with a longer term ... parts of the globe that is warming up fastest today. ...
... and Shinya Yamanaka, MD, PhD, have been elected as members ... in original scientific research. It is one of the highest ... States. They join 70 other scientists who will ... now has 40 current faculty members in the distinguished group. ...
Cached Biology News:A new research report shows effects of climate change in the Arctic are more extensive than expected 2A new research report shows effects of climate change in the Arctic are more extensive than expected 3UCSF scientists honored by National Academy of Sciences 2
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
NEWBORN CALF SERUM AND PLASMA...
Synaptic Vesicle I Sampler Kit 10g each...
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Biology Products: